{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Duineveld C"],"funding":["ZonMw"],"pagination":["715-726"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10105043"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["8(4)"],"pubmed_abstract":["<h4>Introduction</h4>Since 2016, kidney transplantation in patients with atypical hemolytic uremic syndrome (aHUS) in the Netherlands is performed without eculizumab prophylaxis. Eculizumab is given in case of posttransplant aHUS recurrence. Eculizumab therapy is monitored in the CUREiHUS study.<h4>Methods</h4>All participating kidney transplant patients who received eculizumab therapy for a suspected posttransplant aHUS recurrence were evaluated. Overall recurrence rate was monitored prospectively at Radboud University Medical Center.<h4>Results</h4>In the period from January 2016 until October 2020, we included 15 (12 females, 3 males; median age 42 years, range 24-66 years) patients with suspected aHUS recurrence after kidney transplantation in this study. The time interval to recurrenc"],"journal":["Kidney international reports"],"pubmed_title":["Eculizumab Rescue Therapy in Patients With Recurrent Atypical Hemolytic Uremic Syndrome After Kidney Transplantation."],"pmcid":["PMC10105043"],"funding_grant_id":["836031008"],"pubmed_authors":["Wetzels JFM","Berger DS","Horuz-Engels FAPT","van Rooij RWG","van Zuijlen AD","van den Heuvel LPWJ","Wijnsma KL","Bouwmeester RN","van de Kar NCAJ","de Vries APJ","Keijzer-Veen MG","van Wijk JAE","Duineveld C","Bemelman FJ","van der Heijden JW","Berger SP","Dutch aHUS Working Group","Dorresteijn EM","van de Wetering J","van den Heuvel LP","Bouts AHM","Gracchi V"],"additional_accession":[]},"is_claimable":false,"name":"Eculizumab Rescue Therapy in Patients With Recurrent Atypical Hemolytic Uremic Syndrome After Kidney Transplantation.","description":"<h4>Introduction</h4>Since 2016, kidney transplantation in patients with atypical hemolytic uremic syndrome (aHUS) in the Netherlands is performed without eculizumab prophylaxis. Eculizumab is given in case of posttransplant aHUS recurrence. Eculizumab therapy is monitored in the CUREiHUS study.<h4>Methods</h4>All participating kidney transplant patients who received eculizumab therapy for a suspected posttransplant aHUS recurrence were evaluated. Overall recurrence rate was monitored prospectively at Radboud University Medical Center.<h4>Results</h4>In the period from January 2016 until October 2020, we included 15 (12 females, 3 males; median age 42 years, range 24-66 years) patients with suspected aHUS recurrence after kidney transplantation in this study. The time interval to recurrenc","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Apr","modification":"2026-05-28T17:51:52.454Z","creation":"2025-04-04T14:30:18.097Z"},"accession":"S-EPMC10105043","cross_references":{"pubmed":["37069997"],"doi":["10.1016/j.ekir.2023.01.016"]}}